

L&G Healthcare Breakthrough UCITS ETF



ETF (UCITS compliant) USD Accumulating ETF Class

FUND AIM

The L&G Healthcare Breakthrough UCITS ETF (the "ETF") aims to track the performance of the ROBO Global® Healthcare Technology and Innovation Index TR (the "Index"). More information on the Index can be found on page 2 of this document.

RISK AND REWARD PROFILE



This ETF is rated 6 due to the nature of its investments and its risks.

The rating is calculated based on historical data and may not be a reliable indication of the ETF's future risk profile.

The risk category may shift over time.

The lowest category on the above scale does not mean "risk free."

WHO IS THIS FUND FOR?

- This ETF is designed for investors looking to grow their money in an investment which can form part of their existing savings portfolio
- Although investors can take their money out at any time, this ETF may not be appropriate for those who plan to withdraw their money within five years
- If you do not understand the information in this document, the key investor information document or the prospectus, we recommend that you seek additional information or advice to help you decide if this ETF is suitable for you.


FUND FACTS

Fund size	Base currency	Index	
\$49.9m	USD	ROBO Global® Healthcare Technology and Innovation Index	
Listing date	Domicile	Index ticker	Replication method
2 Jul 2019	Ireland	HTECTR	Physical - full replication

COSTS

Total expense ratio
0.49%

PERFORMANCE (%) IN USD



	1 month	6 months	1 year	3 years	Launch
NAV	1.37	48.80	49.24	-	44.77
Index	1.41	49.23	50.05	-	45.71
Relative	-0.04	-0.43	-0.81	-	-0.94

FUND SNAPSHOT

- **Long-term allocation**
Long-term megatrend that we believe is radically transforming the way we live and work
- **High growth potential**
Aims to capture the outsized growth potential of the healthcare technology industry
- **Leveraging industry expertise**
An index tracking investment strategy that is supported by a team of healthcare technology experts

ANNUAL PERFORMANCE (%)

12 Months to 30 September	2020	2019	2018	2017	2016
NAV	49.24	-	-	-	-
Index	50.05	-	-	-	-
Relative	-0.81	-	-	-	-

Performance for the USD Accumulating ETF class, listed on 2 July 2019. Source: Lipper. Performance assumes all ETF charges have been taken and that all income generated by the investments, after deduction of tax, remains in the ETF.

Past performance is not a guide to the future.


INDEX BREAKDOWN

The breakdowns below relate to the Index. The ETF's portfolio may deviate from the below. All data source LGIM unless otherwise stated. Totals may not sum to 100% due to rounding.



SECTOR (%)

Medical Instruments	26.1
Diagnostics	15.0
Precision Medicine	13.3
Process Automation	12.2
Genomics	11.4
Data Analytics	8.2
Robotics	5.2
Regenerative Medicine	4.5
Telehealth	4.2



CURRENCY (%)

USD	84.4
EUR	6.4
CHF	3.7
GBP	1.6
HKD	1.2
AUD	1.1
DKK	0.9
JPY	0.7



■ Top 10 constituents 16.4%
 ■ Rest of Index 83.6%
 No. of constituents in Index 85

TOP 10 CONSTITUENTS (%)

Novocure	1.9
Fulgent Genetics	1.8
Exact Sciences	1.7
Quidel	1.6
DiaSorin	1.6
Insulet	1.6
Cardiovascular Systems	1.6
Collectis	1.6
Natera	1.5
CareDx	1.5

INDEX DESCRIPTION

The Index aims to track the performance of a basket of companies that are actively engaged in the healthcare technology value-chain.

The index is comprised of companies which are publicly traded on various stock exchanges around the world that have a distinct portion of their business and revenue derived from the field of healthcare technologies, and the potential to grow within this space through innovation and/or market adoption of their products and/or services. Companies are included in the index receive a "HTEC Score" comprised of factors representing (1) the levels of revenue the company receives from innovative healthcare technologies, (2) the levels of investment the firm makes in healthcare technologies, (3) the market and technology leadership of the firm within the universe.

A company is only eligible for inclusion in the Index if it is of a sufficient size (determined by reference to the total market value of its shares) and it is sufficiently "liquid" (a measure of how actively its shares are traded on a daily basis). Within the Index, companies are weighted according a modified HTEC-factor weighting scheme. The Index is rebalanced quarterly in March, June, September and December.

INVESTMENT MANAGER

GO ETF Solutions LLP is the investment manager for each of the exchange traded funds (ETFs) issued by Legal & General UCITS ETF Plc and is responsible for the day-to-day investment management decisions for this ETF. The team is highly experienced with respect to all aspects relating to the management of an ETF portfolio, including collateral management, OTC swap trading, adherence to UCITS regulations and counterparty exposure and monitoring.

KEY RISKS

- The value of an investment and any income taken from it is not guaranteed and can go down as well as up; you may not get back the amount you originally invested.
- Third party service providers (such as counterparties entering into financial derivative instruments with the ETF or the ETF's depository) may go bankrupt and fail to pay money due to the ETF or return property belonging to the ETF.
- As the Index includes micro, small and medium-sized publicly traded companies, the ETF is subject to the risk that such companies may be more vulnerable to adverse business or economic events and greater and more unpredictable price changes than larger companies or the stock market as a whole.
- The ETF is subject to the risks associated with technology-focused companies and are particularly vulnerable to rapid developments in technology (which may leave their products out-of-date), government regulation and competition from domestic and foreign competitors who may have lower production costs. Such companies may also have difficulties establishing and maintaining patents, copyrights, trademarks and trade secrets relating to their products which could negatively affect their value.
- It may not always be possible to buy and sell ETF shares on a stock exchange or at prices closely reflecting the NAV.
- If the Index provider stops calculating the Index or if the ETF's license to track the Index is terminated, the ETF may have to be closed.

For more information, please refer to the key investor information document on our website [↗](#)

TRADING INFORMATION

Exchange	Currency	ISIN	SEDOL	Ticker	Bloomberg
London Stock Exchange	USD	IE00BK5BC677	BKF3JJ5	DOCT	DOCT LN
London Stock Exchange	GBX	IE00BK5BC677	BKF3JQ2	DOCG	DOCG LN
Borsa Italiana	EUR	IE00BK5BC677	BKF3JG2	DOCT	DOCT IM
Deutsche Börse	EUR	IE00BK5BC677	BKF3DF9	XMLH	XMLH GY
SIX Swiss Exchange	CHF	IE00BK5BC677	BMG6920	DOCT	DOCT SW

The currency shown is the trading currency of the listing.



SPOTLIGHT ON LEGAL & GENERAL INVESTMENT MANAGEMENT

We are one of Europe's largest asset managers and a major global investor, with assets under management of £1,240.6 billion (as at 30 June 2020). We work with a wide range of global clients, including pension schemes, sovereign wealth funds, fund distributors and retail investors.

Source: LGIM internal data as at 30 June 2020. The AUM disclosed aggregates the assets managed by LGIM in the UK, LGIMA in the US and LGIM Asia in Hong Kong. The AUM includes the value of securities and derivatives positions.

COUNTRY REGISTRATION

Austria	Denmark	Finland
France	Germany	Ireland
Italy	Luxembourg	Netherlands
Norway	Spain	Sweden
Switzerland	United Kingdom	

AVAILABILITY

ISA eligible	Yes
SIPP eligible	Yes
UK Fund Reporting Status	Yes

TO FIND OUT MORE

Visit [lgimETF.com](https://www.lgimETF.com)

Call **0345 070 8684**

Email fundsales@lgim.com

Lines are open Monday to Friday 8.30am to 6.00pm. We may record and monitor calls. Call charges will vary.

Index Disclaimer

The L&G Healthcare Breakthrough UCITS ETF (the "ETF") is not sponsored, promoted, sold or supported in any other manner by ROBO Global LLC or Solactive AG (the "Index Parties"), nor do the Index Parties offer any express or implicit guarantee or assurance either with regard to the results of using the ROBO Global® Healthcare Technology and Innovation Index (the "Index") and/or Index trademark or the Index price at any time or in any other respect. The Index is calculated and published by Solactive AG. The Index Parties use their best efforts to ensure that the Index is calculated correctly. Irrespective of their obligations towards the Company, the Index Parties have no obligation to point out errors in the Index to third parties including but not limited to investors and/or financial intermediaries of the ETF. Neither publication of the Index by Solactive AG nor the licensing of the Index or Index trademark by ROBO Global LLC for the purpose of use in connection with the ETF constitutes a recommendation by the Index Parties to invest capital in the ETF nor does it in any way represent an assurance or opinion of the Index Parties with regard to any investment in the ETF.

Important Information

Copyright © 2020 Legal & General. This document is subject to copyright. Any unauthorised use is strictly prohibited. All rights are reserved.

Issued by LGIM Managers (Europe) Limited as management company for this fund. Registered in Ireland No. 609677. Registered Office: 33/34 Sir John Rogerson's Quay, Dublin, 2, Ireland. Authorised and Regulated by the Central Bank of Ireland No. C173733.

GO ETF Solutions LLP has been appointed as the discretionary investment manager for this Fund, it is authorised and regulated by the Financial Conduct Authority No.477266.

We are a member of the Irish Funds Association.

All features described in this factsheet are those current at the time of publication and may be changed in the future. Nothing in this factsheet should be construed as advice and it is therefore not a recommendation to buy or sell securities. If in doubt about the suitability of this product, you should seek professional advice. Copies of the prospectus, key investor information document, annual and semi-annual reports & accounts are available free of charge on request or at www.lgimetf.com.

This document is only directed at investors resident in jurisdictions where our funds are registered for sale. It is not an offer or invitation to persons outside of those jurisdictions. We reserve the right to reject any applications from outside of such jurisdictions.